Precision (or ‘personalised’) medicine uses data about a person’s genes (genomics), along with additional information on their cancer, to understand the unique pathways of a disease or treatment response in that person, and target their treatment accordingly.
Precision Oncology Ireland will use cutting-edge technologies to generate unique genetic and molecular profiles for each patient’s cancer. The key competitive advantage of the programme lies in the innovative computational methods applied to make sense of these profiles, and decipher what drives each individual cancer. The results will be better cancer diagnostics, personalised cancer treatment, and faster drug discovery and development.
The outcomes of this research programme will range from diagnostic tests for cancer based on personal molecular markers, novel drugs which specifically target cancer cells, and improved synergistic drug combinations. The programme will also provide key infrastructural supports to researchers, co-ordinating access to tumour biobanks, and allowing access to state-of-the-art technologies.
Key Research Goals
Our research spans the spectrum from early-stage research focused on better understanding the disease, all the way through to diagnostics and treatments in testing. Through collaboration, POI will accelerate the development of new diagnostics and treatments, and allow patients to benefit from research advances at an earlier stage.
Ultimately, our goal is to enable clinicians to 'treat the right patient with the right drug at the right time', minimising side-effects, reducing healthcare costs, and improving the outcome for patients and their families.